Novel Hybrid Growth Factor for Immune Reconstitution in Sepsis

Abstract Novel Hybrid Growth Factor for Immune Reconstitution in Sepsis Sepsis is a major clinical problem with more than a 40% mortality rate, and is the leading cause of death in intensive care units. Despite a great deal of investment of time and moneyin basic and clinical research including more than 40 clinical trials, there is no FDA-approved drug for sepsis. Historically, experimental sepsis treatments focused on the early phase which consists of a systemic inflammatory response syndrome (SIRS) characterized by excessive production of pro-inflammatory mediators by immune cells. Although experimental treatment modalities targeting inflammatory mediators (e.g. TNF-a or IL-1) were often effective in animal models, they failed in human clinical trials.It is now understood that following the early acute phase, there is a transition to a compensatory anti-inflammatory response syndrome (CARS) to limit damage, leading to immunosuppression and promotion of chronic infection . In the chronic phase of sepsis